Efficacy

Tagrisso (Osimertinib) Efficacy in Lung Cancer

Tagrisso (osimertinib) is a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that has shown significant efficacy in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Clinical trials have demonstrated that osimertinib is effective in patients with NSCLC harboring exon 19 deletions or exon 21 L858R mutations, which are common EGFR mutations in this cancer type. In the FLAURA trial, osimertinib significantly improved progression-free survival (PFS) compared to standard EGFR TKIs (gefitinib or erlotinib) in the first-line treatment setting for patients with these mutations.

Moreover, osimertinib has shown efficacy in patients with central nervous system (CNS) metastases, a common and challenging complication of NSCLC. Osimertinib's ability to penetrate the blood-brain barrier allows for effective targeting of CNS lesions, which was demonstrated in the AURA3 trial where it improved PFS compared to platinum-based therapy in patients with T790M-positive NSCLC and brain metastases who had progressed after initial EGFR TKI therapy.

Tabrecta (Capmatinib) Efficacy in Lung Cancer

Tabrecta (capmatinib) is a selective inhibitor of the MET proto-oncogene, which has been identified as a driver in certain types of non-small cell lung cancer (NSCLC), particularly those with MET exon 14 skipping mutations. The GEOMETRY mono-1 trial evaluated the efficacy of capmatinib in patients with MET exon 14-altered advanced NSCLC. The results showed a notable objective response rate (ORR) in both treatment-naive patients and those who had received prior treatment, indicating capmatinib's potential as an effective targeted therapy for this patient population.

Capmatinib's approval was based on the efficacy outcomes from this trial, which highlighted its role in addressing a previously unmet need for patients with MET exon 14 skipping mutation-positive NSCLC. The treatment has been associated with rapid and durable responses, offering a new therapeutic option for a subset of NSCLC patients with limited targeted treatment alternatives. As research continues, the efficacy of capmatinib in broader NSCLC populations and in combination with other therapies is being explored to further understand its potential benefits in lung cancer management.